FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034711208> ?p ?o ?g. }

• W2034711208 abstract "Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DCThe incidence of hepatocellular carcinoma (HCC) is increasing not only in Asia but also in Europe and United States. Since the high-risk group of either primary or secondary HCC development seems to be clearer than in the other types of tumors, it is likely that chemopreventive agents will be beneficial in improving the prognosis of HCC. No chemopreventive agent, however, has been approved against HCC yet. Since neovascularization plays a pivotal role in HCC, an angiostatic agent is considered as one of the promising approaches. Although the multi-kinase inhibitor, sorafenib, has recently been approved for advanced HCC in many countries, there seem to be several serious concerns to employ this agent for chemoprevention against HCC. As long-term administration is required and the drug metabolism is usually hypoactive in patients with cirrhosis, a safety-proved agent would be preferable for chemoprevention against HCC. Most patients show adverse reactions with sorafenib, and several symptoms are very severe. The aim of this study was to develop a vascular endothelial growth factor (VEGF)-targeted new anti-angiogenic therapy against HCC using combination of clinically available safe agents. Moreover, since it is an imperative issue to find serum predictive biomarkers of clinical benefit, we tried to find a useful marker. We previously reported that the clinically used anti-osteoporosis agent; vitamin K (VK), and the anti-hypertensive agent; angiotensin-converting enzyme inhibitor (ACE-I), exerted potent anti-angiogenic activities along with suppression of VEGF at clinically comparable low doses in a basic study. In the clinical practice, the combination treatment of VK (menatetrenone; 45 mg/day) and ACE-I (perindopril; 4 mg/day) markedly inhibited the cumulative recurrence of HCC along with suppression of VEGF for 54 months after curative therapy. The serum level of alpha fetoprotein-L3 (AFP-L3), which indicates the presence of latent HCC, was also suppressed almost in parallel with VEGF. Chronological studies reveled that the VEGF and AFP-L3 were significantly decreased in patients without recurrence at 6 and 12 months after the treatment, respectively. We also examined the alteration of soluble form of VEGF receptor-2 (sVEGFR-2), and found that a significant suppression of sVEGFR-2 level could be achieved within three months after the treatment. Collectively, the alteration of the serum level of VEGF-related proteins, especially VEGFR-2, could be used as a biomarker for the therapeutic efficacy. These results indicate that this combination treatment may represent a potential new strategy for secondary chemoprevention of HCC with effective prediction of the clinical outcome since both agents are widely used in the clinical practice without serious side effects.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3439." @default.
• W2034711208 created "2016-06-24" @default.
• W2034711208 creator A5015134990 @default.
• W2034711208 creator A5023553051 @default.
• W2034711208 creator A5031685667 @default.
• W2034711208 creator A5075622734 @default.
• W2034711208 creator A5076532126 @default.
• W2034711208 creator A5079744367 @default.
• W2034711208 date "2010-04-15" @default.
• W2034711208 modified "2023-09-25" @default.
• W2034711208 title "Abstract 3439: An alternative VEGF-targeted therapy and possible prediction against hepatocellular carcinoma (HCC) using combination of clinically available agents" @default.
• W2034711208 doi "https://doi.org/10.1158/1538-7445.am10-3439" @default.
• W2034711208 hasPublicationYear "2010" @default.
• W2034711208 type Work @default.
• W2034711208 sameAs 2034711208 @default.
• W2034711208 citedByCount "1" @default.
• W2034711208 countsByYear W20347112082020 @default.
• W2034711208 crossrefType "proceedings-article" @default.
• W2034711208 hasAuthorship W2034711208A5015134990 @default.
• W2034711208 hasAuthorship W2034711208A5023553051 @default.
• W2034711208 hasAuthorship W2034711208A5031685667 @default.
• W2034711208 hasAuthorship W2034711208A5075622734 @default.
• W2034711208 hasAuthorship W2034711208A5076532126 @default.
• W2034711208 hasAuthorship W2034711208A5079744367 @default.
• W2034711208 hasConcept C121608353 @default.
• W2034711208 hasConcept C126322002 @default.
• W2034711208 hasConcept C143998085 @default.
• W2034711208 hasConcept C167734588 @default.
• W2034711208 hasConcept C197934379 @default.
• W2034711208 hasConcept C2776694085 @default.
• W2034711208 hasConcept C2776999253 @default.
• W2034711208 hasConcept C2777025900 @default.
• W2034711208 hasConcept C2777214474 @default.
• W2034711208 hasConcept C2777802072 @default.
• W2034711208 hasConcept C2778019345 @default.
• W2034711208 hasConcept C2778695046 @default.
• W2034711208 hasConcept C2780394083 @default.
• W2034711208 hasConcept C2781230642 @default.
• W2034711208 hasConcept C502942594 @default.
• W2034711208 hasConcept C71924100 @default.
• W2034711208 hasConcept C98274493 @default.
• W2034711208 hasConceptScore W2034711208C121608353 @default.
• W2034711208 hasConceptScore W2034711208C126322002 @default.
• W2034711208 hasConceptScore W2034711208C143998085 @default.
• W2034711208 hasConceptScore W2034711208C167734588 @default.
• W2034711208 hasConceptScore W2034711208C197934379 @default.
• W2034711208 hasConceptScore W2034711208C2776694085 @default.
• W2034711208 hasConceptScore W2034711208C2776999253 @default.
• W2034711208 hasConceptScore W2034711208C2777025900 @default.
• W2034711208 hasConceptScore W2034711208C2777214474 @default.
• W2034711208 hasConceptScore W2034711208C2777802072 @default.
• W2034711208 hasConceptScore W2034711208C2778019345 @default.
• W2034711208 hasConceptScore W2034711208C2778695046 @default.
• W2034711208 hasConceptScore W2034711208C2780394083 @default.
• W2034711208 hasConceptScore W2034711208C2781230642 @default.
• W2034711208 hasConceptScore W2034711208C502942594 @default.
• W2034711208 hasConceptScore W2034711208C71924100 @default.
• W2034711208 hasConceptScore W2034711208C98274493 @default.
• W2034711208 hasLocation W20347112081 @default.
• W2034711208 hasOpenAccess W2034711208 @default.
• W2034711208 hasPrimaryLocation W20347112081 @default.
• W2034711208 hasRelatedWork W1974342793 @default.
• W2034711208 hasRelatedWork W1994843872 @default.
• W2034711208 hasRelatedWork W2028667086 @default.
• W2034711208 hasRelatedWork W2132423540 @default.
• W2034711208 hasRelatedWork W2166310425 @default.
• W2034711208 hasRelatedWork W2406898168 @default.
• W2034711208 hasRelatedWork W2409763824 @default.
• W2034711208 hasRelatedWork W2528009538 @default.
• W2034711208 hasRelatedWork W2552346451 @default.
• W2034711208 hasRelatedWork W2576015049 @default.
• W2034711208 hasRelatedWork W2964450000 @default.
• W2034711208 hasRelatedWork W2994788491 @default.
• W2034711208 hasRelatedWork W2998954273 @default.
• W2034711208 hasRelatedWork W3035898475 @default.
• W2034711208 hasRelatedWork W3036421504 @default.
• W2034711208 hasRelatedWork W306580226 @default.
• W2034711208 hasRelatedWork W3128007172 @default.
• W2034711208 hasRelatedWork W3142097032 @default.
• W2034711208 hasRelatedWork W3144711121 @default.
• W2034711208 hasRelatedWork W2162162632 @default.
• W2034711208 isParatext "false" @default.
• W2034711208 isRetracted "false" @default.
• W2034711208 magId "2034711208" @default.
• W2034711208 workType "article" @default.